{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:14:24Z","timestamp":1787037264607,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>N-acetylcysteine (NAC), which is specifically involved in airway mucus clearance and antioxidation, is recommended by the treatment guideline for non-cystic fibrosis bronchiectasis (NCFB). However, there is little clinical evidence of its long-term efficacy concerning quality of life (QoL) and exacerbation in patients with NCFB. In addition, the influences of NAC on airway bacterial colonization, chronic inflammation and oxidative stress in NCFB are also unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>NINCFB is a prospective, multicentre, double-blind, randomised, placebo-controlled trial that will recruit 119 patients with NCFB and randomly divide them into an NAC group (<jats:italic>n<\/jats:italic>\u00a0=\u200979) and a control group (<jats:italic>n<\/jats:italic>\u00a0=\u200940). Participants in the NAC group will receive 600\u2009mg oral NAC twice daily for 52\u2009weeks, while patients in the control group will receive 600\u2009mg placebo twice daily for 52\u2009weeks. The information at baseline will be collected once participants are enrolled. The primary endpoints are the changes in St George\u2019s Respiratory Questionnaire scores and the number of exacerbations in 52\u2009weeks. The secondary endpoints are the 16S rRNA of sputum and the levels of inflammatory factors and oxidative stressors in sputum and serum. Other data related to radiography, lung function tests, number of oral and\/or intravenous antibiotic therapies and adverse events (AEs) will also be analysed. Further subgroup analysis distinguished by the severity of disease, severity of lung function, airway bacterial colonization and exacerbation frequency will be performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The objective of this study is to determine the long-term efficacy of NAC on QoL and exacerbation of NCFB and to explore the effectiveness of NAC for antibiosis, anti-inflammation and antioxidation in NCFB. The study results will provide high-quality clinical proof for the revision and optimization of treatment guidelines and for expert consensus on NCFB treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The trial was registered on the Chinese Clinical Trial Register at April 11, 2020 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/chictr.org.cn\">chictr.org.cn<\/jats:ext-link>, ChiCTR2000031817).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-02202-9","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T11:40:49Z","timestamp":1667821249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of N-acetylcysteine in patients with non-cystic fibrosis bronchiectasis (NINCFB): study protocol for a multicentre, double-blind, randomised, placebo-controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Yue","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-4758","authenticated-orcid":false,"given":"Fuqiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"issue":"1","key":"2202_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12890-020-1050-0","volume":"20","author":"S Aliberti","year":"2020","unstructured":"Aliberti S, et al. Prevalence and incidence of bronchiectasis in Italy. BMC Pulm Med. 2020;20(1):15. https:\/\/doi.org\/10.1186\/s12890-020-1050-0.","journal-title":"BMC Pulm Med"},{"issue":"12","key":"2202_CR2","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/alr.22436","volume":"9","author":"SN Somani","year":"2019","unstructured":"Somani SN, et al. Prevalence and characterization of chronic rhinosinusitis in patients with non-cystic fibrosis bronchiectasis at a tertiary care center in the United States. Int Forum Allergy Rhinol. 2019;9(12):1424\u20139. https:\/\/doi.org\/10.1002\/alr.22436.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"2202_CR3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1378\/chest.11-2209","volume":"142","author":"AE Seitz","year":"2012","unstructured":"Seitz AE, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142(2):432\u20139. https:\/\/doi.org\/10.1378\/chest.11-2209.","journal-title":"Chest"},{"issue":"5","key":"2202_CR4","first-page":"379","volume":"52","author":"YM Zhou","year":"2013","unstructured":"Zhou YM, et al. The prevalence and risk factors of bronchiectasis in residents aged 40 years old and above in seven cities in China. Zhonghua Nei Ke Za Zhi. 2013;52(5):379\u201382.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"Suppl 1","key":"2202_CR5","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2010.136119","volume":"65","author":"MC Pasteur","year":"2010","unstructured":"Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1\u201358. https:\/\/doi.org\/10.1136\/thx.2010.136119.","journal-title":"Thorax"},{"issue":"3","key":"2202_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pedneo.2019.09.013","volume":"61","author":"M Poeta","year":"2020","unstructured":"Poeta M, et al. Non-cystic fibrosis bronchiectasis in children and adolescents: neglected and emerging issues. Pediatr Neonatol. 2020;61(3):255\u201362. https:\/\/doi.org\/10.1016\/j.pedneo.2019.09.013.","journal-title":"Pediatr Neonatol"},{"issue":"6","key":"2202_CR7","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1164\/rccm.201303-0411CI","volume":"188","author":"PJ McShane","year":"2013","unstructured":"McShane PJ, et al. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647\u201356. https:\/\/doi.org\/10.1164\/rccm.201303-0411CI.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2202_CR8","doi-asserted-by":"publisher","DOI":"10.1590\/1806-3713\/e20190122","volume":"45","author":"MC Pereira","year":"2019","unstructured":"Pereira MC, et al. Brazilian consensus on non-cystic fibrosis bronchiectasis. J Bras Pneumol. 2019;45(4):e20190122. https:\/\/doi.org\/10.1590\/1806-3713\/e20190122.","journal-title":"J Bras Pneumol"},{"issue":"5","key":"2202_CR9","doi-asserted-by":"publisher","first-page":"Cd001289","DOI":"10.1002\/14651858.CD001289.pub2","volume":"2014","author":"M Wilkinson","year":"2014","unstructured":"Wilkinson M, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2014;2014(5):Cd001289. https:\/\/doi.org\/10.1002\/14651858.CD001289.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2202_CR10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1164\/rccm.201906-1219OC","volume":"201","author":"KA Ramsey","year":"2020","unstructured":"Ramsey KA, et al. Airway mucus hyperconcentration in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2020;201(6):661\u201370. https:\/\/doi.org\/10.1164\/rccm.201906-1219OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"2202_CR11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/resp.13398","volume":"23","author":"SC Bell","year":"2018","unstructured":"Bell SC, Elborn JS, Byrnes CA. Bronchiectasis: treatment decisions for pulmonary exacerbations and their prevention. Respirology. 2018;23(11):1006\u201322. https:\/\/doi.org\/10.1111\/resp.13398.","journal-title":"Respirology"},{"key":"2202_CR12","doi-asserted-by":"publisher","unstructured":"Chang AB, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021;58(2). https:\/\/doi.org\/10.1183\/13993003.02990-2020.","DOI":"10.1183\/13993003.02990-2020"},{"issue":"5","key":"2202_CR13","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1183\/09031936.00119114","volume":"45","author":"JD Chalmers","year":"2015","unstructured":"Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446\u201362. https:\/\/doi.org\/10.1183\/09031936.00119114.","journal-title":"Eur Respir J"},{"key":"2202_CR14","volume-title":"Acetylcysteine for patients requiring mucous secretion clearance: a review of clinical effectiveness and safety","author":"S Banerjee","year":"2019","unstructured":"Banerjee S, McCormack S. CADTH Rapid Response Reports. In:  Acetylcysteine for patients requiring mucous secretion clearance: a review of clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 2019 Canadian Agency for Drugs and Technologies in Health; 2019."},{"issue":"2","key":"2202_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ccm.2012.02.008","volume":"33","author":"GB Nair","year":"2012","unstructured":"Nair GB, Ilowite JS. Pharmacologic agents for mucus clearance in bronchiectasis. Clin Chest Med. 2012;33(2):363\u201370. https:\/\/doi.org\/10.1016\/j.ccm.2012.02.008.","journal-title":"Clin Chest Med"},{"issue":"1","key":"2202_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12958-019-0468-9","volume":"17","author":"R Jannatifar","year":"2019","unstructured":"Jannatifar R, et al. Effects of N-acetyl-cysteine supplementation on sperm quality, chromatin integrity and level of oxidative stress in infertile men. Reprod Biol Endocrinol. 2019;17(1):24. https:\/\/doi.org\/10.1186\/s12958-019-0468-9.","journal-title":"Reprod Biol Endocrinol"},{"key":"2202_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.rmed.2016.06.015","volume":"117","author":"F Blasi","year":"2016","unstructured":"Blasi F, et al. The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190\u20137. https:\/\/doi.org\/10.1016\/j.rmed.2016.06.015.","journal-title":"Respir Med"},{"issue":"3","key":"2202_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12275-014-4068-2","volume":"52","author":"DJ Hassett","year":"2014","unstructured":"Hassett DJ, Borchers MT, Panos RJ. Chronic obstructive pulmonary disease (COPD): evaluation from clinical, immunological and bacterial pathogenesis perspectives. J Microbiol. 2014;52(3):211\u201326. https:\/\/doi.org\/10.1007\/s12275-014-4068-2.","journal-title":"J Microbiol"},{"issue":"1","key":"2202_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pupt.2005.12.007","volume":"20","author":"AM Sadowska","year":"2007","unstructured":"Sadowska AM, Manuel YKB, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther. 2007;20(1):9\u201322. https:\/\/doi.org\/10.1016\/j.pupt.2005.12.007.","journal-title":"Pulm Pharmacol Ther"},{"key":"2202_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/891752","volume":"2011","author":"ML Bartoli","year":"2011","unstructured":"Bartoli ML, et al. Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases. Mediators Inflamm. 2011;2011:891752. https:\/\/doi.org\/10.1155\/2011\/891752.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"2202_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-019-1042-x","volume":"20","author":"Q Qi","year":"2019","unstructured":"Qi Q, et al. Effect of N-acetylcysteine on exacerbations of bronchiectasis (BENE): a randomized controlled trial. Respir Res. 2019;20(1):73. https:\/\/doi.org\/10.1186\/s12931-019-1042-x.","journal-title":"Respir Res"},{"issue":"2","key":"2202_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/resp.12970","volume":"22","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, et al. Evaluating the clinical COPD questionnaire: a systematic review. Respirology. 2017;22(2):251\u201362. https:\/\/doi.org\/10.1111\/resp.12970.","journal-title":"Respirology"},{"issue":"8","key":"2202_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/phm.0000000000000667","volume":"96","author":"M Paneroni","year":"2017","unstructured":"Paneroni M, et al. Aerobic exercise training in very severe chronic obstructive pulmonary disease: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2017;96(8):541\u20138. https:\/\/doi.org\/10.1097\/phm.0000000000000667.","journal-title":"Am J Phys Med Rehabil"},{"issue":"8","key":"2202_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/thoraxjnl-2015-207315","volume":"71","author":"A Spinou","year":"2016","unstructured":"Spinou A, et al. The validity of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. Thorax. 2016;71(8):683\u201394. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-207315.","journal-title":"Thorax"},{"key":"2202_CR25","doi-asserted-by":"publisher","unstructured":"Molimard M, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017;49(2). https:\/\/doi.org\/10.1183\/13993003.01794-2016.","DOI":"10.1183\/13993003.01794-2016"},{"key":"2202_CR26","doi-asserted-by":"publisher","unstructured":"Garth J, Barnes JW, Krick S. Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases. Int J Mol Sci. 2018;19(11). https:\/\/doi.org\/10.3390\/ijms19113402.","DOI":"10.3390\/ijms19113402"},{"key":"2202_CR27","doi-asserted-by":"publisher","unstructured":"Men\u00e9ndez R, et al. Systemic inflammation during and after bronchiectasis exacerbations: impact of Pseudomonas aeruginosa. J Clin Med. 2020;9(8). https:\/\/doi.org\/10.3390\/jcm9082631.","DOI":"10.3390\/jcm9082631"},{"issue":"1","key":"2202_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1034\/j.1399-3003.2000.16a26.x","volume":"16","author":"L Zheng","year":"2000","unstructured":"Zheng L, et al. Endothelin-1 in stable bronchiectasis. Eur Respir J. 2000;16(1):146\u20139. https:\/\/doi.org\/10.1034\/j.1399-3003.2000.16a26.x.","journal-title":"Eur Respir J"},{"issue":"7","key":"2202_CR29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/resp.12582","volume":"20","author":"WJ Guan","year":"2015","unstructured":"Guan WJ, et al. Sputum matrix metalloproteinase-8 and -9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: clinical correlates and prognostic implications. Respirology. 2015;20(7):1073\u201381. https:\/\/doi.org\/10.1111\/resp.12582.","journal-title":"Respirology"},{"issue":"1","key":"2202_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.semarthrit.2017.12.002","volume":"48","author":"A N\u00e9el","year":"2018","unstructured":"N\u00e9el A, et al. Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. Semin Arthritis Rheum. 2018;48(1):70\u20136. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.12.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2202_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3906\/sag-1503-99","volume":"50","author":"AH Gedik","year":"2020","unstructured":"Gedik AH, et al. Total oxidant and antioxidant status and paraoxonase 1 levels of children with noncystic fibrosis bronchiectasis. Turk J Med Sci. 2020;50(1):1\u20137. https:\/\/doi.org\/10.3906\/sag-1503-99.","journal-title":"Turk J Med Sci"},{"issue":"2","key":"2202_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/bf02912934","volume":"21","author":"RR Rai","year":"2006","unstructured":"Rai RR, Phadke MS. Plasma oxidant-antioxidant status in different respiratory disorders. Indian J Clin Biochem. 2006;21(2):161\u20134. https:\/\/doi.org\/10.1007\/bf02912934.","journal-title":"Indian J Clin Biochem"},{"key":"2202_CR33","doi-asserted-by":"publisher","unstructured":"Costa JC, et al. The bronchiectasis severity index and FACED score for assessment of the severity of bronchiectasis. Pulmonology. 2018. https:\/\/doi.org\/10.1016\/j.rppnen.2017.08.009.","DOI":"10.1016\/j.rppnen.2017.08.009"},{"issue":"1","key":"2202_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2049-6958-7-3","volume":"7","author":"O Ozalp","year":"2012","unstructured":"Ozalp O, et al. Extrapulmonary features of bronchiectasis: muscle function, exercise capacity, fatigue, and health status. Multidiscip Respir Med. 2012;7(1):3. https:\/\/doi.org\/10.1186\/2049-6958-7-3.","journal-title":"Multidiscip Respir Med"},{"issue":"1","key":"2202_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1081\/copd-200050513","volume":"2","author":"PW Jones","year":"2005","unstructured":"Jones PW, St. George\u2019s respiratory questionnaire: MCID. Copd. 2005;2(1):75\u20139. https:\/\/doi.org\/10.1081\/copd-200050513.","journal-title":"Copd"},{"issue":"58","key":"2202_CR36","first-page":"31","volume":"19","author":"R Gruen","year":"2006","unstructured":"Gruen R, et al. Specialist outreach clinics in primary care and rural hospital settings (Cochrane review). Community Eye Health. 2006;19(58):31.","journal-title":"Community Eye Health"},{"issue":"2","key":"2202_CR37","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.chest.2020.02.045","volume":"158","author":"P Rebelo","year":"2020","unstructured":"Rebelo P, et al. Minimal clinically important differences for patient-reported outcome measures of fatigue in patients with COPD following pulmonary rehabilitation. Chest. 2020;158(2):550\u201361. https:\/\/doi.org\/10.1016\/j.chest.2020.02.045.","journal-title":"Chest"},{"issue":"3","key":"2202_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ppul.23031","volume":"50","author":"RL Marsh","year":"2015","unstructured":"Marsh RL, et al. Detection of biofilm in bronchoalveolar lavage from children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol. 2015;50(3):284\u201392. https:\/\/doi.org\/10.1002\/ppul.23031.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"2202_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1378\/chest.12-1763","volume":"144","author":"D Bilton","year":"2013","unstructured":"Bilton D, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013;144(1):215\u201325. https:\/\/doi.org\/10.1378\/chest.12-1763.","journal-title":"Chest"},{"issue":"12","key":"2202_CR40","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/thoraxjnl-2014-205587","volume":"69","author":"D Bilton","year":"2014","unstructured":"Bilton D, et al. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014;69(12):1073\u20139. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205587.","journal-title":"Thorax"},{"issue":"12","key":"2202_CR41","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.rmed.2011.07.019","volume":"105","author":"F Kellett","year":"2011","unstructured":"Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011;105(12):1831\u20135. https:\/\/doi.org\/10.1016\/j.rmed.2011.07.019.","journal-title":"Respir Med"},{"issue":"5","key":"2202_CR42","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.rmed.2011.12.021","volume":"106","author":"CH Nicolson","year":"2012","unstructured":"Nicolson CH, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012;106(5):661\u20137. https:\/\/doi.org\/10.1016\/j.rmed.2011.12.021.","journal-title":"Respir Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-02202-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02202-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T11:43:11Z","timestamp":1667821391000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-02202-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2202"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-02202-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is approved by the Biomedical Ethics Review Committee of West China Hospital of Sichuan University [Approval Number: 2019(1076)]. We have also obtained ethical approval from all the participating hospitals. All participants will give written informed consent (officiated by a member of the research team) prior to entry into the study and will be made aware that participation is strictly voluntary. Participants may withdraw from the study at any time. The findings will be published in scientific and conference presentations. All data will be recorded and analysed anonymously to protect patient privacy. The trial was registered on the Chinese Clinical Trial Registry website () on April 11, 2020 (Registration number: ChiCTR2000031817).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"401"}}